Germline genetic risk stratification in ALL? GATA get more information
Menée à partir d'une étude d'association sur le génome entier réalisée auprès de 2 597 enfants atteints d'une leucémie aiguë lymphoblastique à risque élevé de récidive et validée sur une cohorte de 491 patients supplémentaires, cette étude évalue l'association entre des polymorphismes à simple nucléotide du gène GATA3 et la présence d'une maladie résiduelle minimale après un traitement d'induction ainsi que le risque de récidive
Over the past several decades outcomes for pediatric acute lymphoblastic leukemia (ALL) have improved dramatically,1yet 10-20%of patients still relapse in some subsets of disease.2,3Relapsed disease is difficult to treat and has mortality of nearly 50% even in the modern era. Thus predicting relapse has become an important goal to stratify patients by risk and potentially to modify therapy. Long-established risk factors for relapse include age at diagnosis, white blood cell count at diagnosis, and DNA index. More recently, minimal residual disease (MRD) assessed by flow cytometry or polymerase chain reaction at the end of induction has emerged as a strong predictor of relapse. To this, the current study by Zhang et al4adds host germline genetics, which predicted suboptimal response to induction (i.e. high MRD) and relapse independently of most baseline risk factors in a large genome-wide association study (GWAS) of high-risk pediatric B-ALL patients.
Journal of the National Cancer Institute , éditorial en libre accès, 2019